{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:01:31Z","timestamp":1790107291997,"version":"4.0.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.esmoop.2023.102034","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T17:35:12Z","timestamp":1697823312000},"page":"102034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7465-9591","authenticated-orcid":false,"given":"Y.","family":"Tomita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6925-2327","authenticated-orcid":false,"given":"R.J.","family":"Motzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-3217","authenticated-orcid":false,"given":"T.K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2212-080X","authenticated-orcid":false,"given":"B.I.","family":"Rini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0563-4160","authenticated-orcid":false,"given":"H.","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2048-4263","authenticated-orcid":false,"given":"M.","family":"Oya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5734-3480","authenticated-orcid":false,"given":"L.","family":"Albiges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Aizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4967-0382","authenticated-orcid":false,"given":"Y.","family":"Umeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"di Pietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schmidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2023.102034_bib3","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdz056","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Escudier","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2023.102034_bib4","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.annonc.2020.11.016","article-title":"Recent eUpdate to the ESMO clinical practice guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Powles","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2023.102034_bib5","series-title":"Prescribing information","year":"2022"},{"key":"10.1016\/j.esmoop.2023.102034_bib6","series-title":"Prescribing information","year":"2022"},{"key":"10.1016\/j.esmoop.2023.102034_bib7","series-title":"Summary of product characteristics","year":"2023"},{"key":"10.1016\/j.esmoop.2023.102034_bib8","series-title":"Summary of product characteristics","year":"2021"},{"key":"10.1016\/j.esmoop.2023.102034_bib9","series-title":"Prescribing information (Japan)","year":"2019"},{"key":"10.1016\/j.esmoop.2023.102034_bib10","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2023.102034_bib11","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.annonc.2020.04.010","article-title":"Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma","volume":"31","author":"Choueiri","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2023.102034_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101210","article-title":"Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib vs sunitinib by IMDC risk group in patients with advanced renal cell carcinoma","volume":"8","author":"Haanen","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2023.102034_bib13","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.102034_bib14","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.3390\/cancers12123750","article-title":"Individualizing systemic therapies in first Line treatment and beyond for advanced renal cell carcinoma","volume":"12","author":"Khan","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2023.102034_bib15","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2023.102034_bib16","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2023.102034_bib17","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2023.102034_bib18","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2023.102034_bib19","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.clgc.2018.04.007","article-title":"Is it possible to improve prognostic classification in patients affected by metastatic renal cell carcinoma with an intermediate or poor prognosis?","volume":"16","author":"Iacovelli","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.esmoop.2023.102034_bib20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.eururo.2019.10.025","article-title":"Efficacy of nivolumab plus ipilimumab according to number of IMDC risk factors in CheckMate 214","volume":"77","author":"Escudier","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.esmoop.2023.102034_bib21","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","article-title":"Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial","volume":"14","author":"Motzer","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2023.102034_bib22","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/jjco\/hyw103","article-title":"Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study","volume":"46","author":"Tomita","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.102034_bib23","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/cas.13232","article-title":"Overall survival of first-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study","volume":"108","author":"Oya","year":"2017","journal-title":"Cancer Sci"},{"key":"10.1016\/j.esmoop.2023.102034_bib24","article-title":"Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101","volume":"7","author":"Tomita","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2023.102034_bib25","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1200\/JCO.2021.39.15_suppl.4500","article-title":"Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): results from 42-month follow-up of KEYNOTE-426","volume":"39","author":"Rini","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.102034_bib26","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/cncr.34180","article-title":"Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma","volume":"128","author":"Motzer","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2023.102034_bib27","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.euo.2023.01.010","article-title":"Survival by depth of response and efficacy by International Metastatic Renal Cell Carcinoma Database Consortium subgroup with lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma: analysis of the phase 3 randomized CLEAR study","volume":"6","author":"Gr\u00fcnwald","year":"2023","journal-title":"Eur Uro Oncol"},{"key":"10.1016\/j.esmoop.2023.102034_bib28","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1470-2045(23)00049-9","article-title":"Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study","volume":"24","author":"Choueiri","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2023.102034_bib29","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2023.102034_bib30","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.euo.2021.03.001","article-title":"First-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis","volume":"4","author":"Quhal","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.esmoop.2023.102034_bib31","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1158\/1078-0432.CCR-19-3323","article-title":"Targeting PD-1 or PD-L1 in metastatic kidney cancer: combination therapy in the first-line setting","volume":"26","author":"Aggen","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2023.102034_bib32","doi-asserted-by":"crossref","first-page":"eaav7431","DOI":"10.1126\/scitranslmed.aav7431","article-title":"Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy","volume":"12","author":"Mayoux","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.esmoop.2023.102034_bib33","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s40425-019-0746-2","article-title":"Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial","volume":"7","author":"Vaishampayan","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.esmoop.2023.102034_bib34","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.eururo.2017.03.037","article-title":"Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in CheckMate 025","volume":"72","author":"Escudier","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.esmoop.2023.102034_bib35","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s12026-020-09138-4","article-title":"Hyperprogressive disease in patients with advanced renal cell carcinoma: a new pattern of post-treatment cancer behavior","volume":"68","author":"Zheng","year":"2020","journal-title":"Immunol Res"},{"key":"10.1016\/j.esmoop.2023.102034_bib36","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2147\/ITT.S240889","article-title":"Immunotherapeutic targets and therapy for renal cell carcinoma","volume":"9","author":"Sepe","year":"2020","journal-title":"Immunotargets Ther"},{"key":"10.1016\/j.esmoop.2023.102034_bib37","article-title":"A\u00a0novel immune-related model to predict prognosis and responsiveness to checkpoint and angiogenesis blockade therapy in advanced renal cancer","volume":"13","author":"Chen","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmoop.2023.102034_bib38","article-title":"Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma","volume":"10","author":"Motzer","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.esmoop.2023.102034_bib39","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3390\/cells12010180","article-title":"Identification and validation of the prognostic panel in clear cell renal cell carcinoma based on resting mast cells for prediction of distant metastasis and immunotherapy response","volume":"12","author":"Su","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.esmoop.2023.102034_bib40","doi-asserted-by":"crossref","first-page":"5985","DOI":"10.3390\/cancers14235985","article-title":"High serum levels of IL-6 predict poor responses in patients treated with pembrolizumab plus axitinib for advanced renal cell carcinoma","volume":"14","author":"Sang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2023.102034_bib41","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1186\/s12967-022-03601-6","article-title":"The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study","volume":"20","author":"Rebuzzi","year":"2022","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.esmoop.2023.102034_bib42","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211019642","article-title":"Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)","volume":"13","author":"Rebuzzi","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.esmoop.2023.102034_bib43","first-page":"2417","article-title":"Prognostic value of absolute lymphocyte count in patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab","volume":"12","author":"Ueda","year":"2023","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.esmoop.2023.102034_bib44","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/iju.15198","article-title":"Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinoma","volume":"30","author":"Tomiyama","year":"2023","journal-title":"Int J Urol"},{"key":"10.1016\/j.esmoop.2023.102034_bib45","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1158\/1078-0432.CCR-21-1688","article-title":"Association of neutrophil-to-lymphocyte ratio with efficacy of first-line avelumab plus axitinib vs. sunitinib in patients with advanced renal cell carcinoma enrolled in the phase 3 JAVELIN Renal 101 trial","volume":"28","author":"Bilen","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2023.102034_bib46","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/s41591-020-1044-8","article-title":"Avelumab plus axitinib versus\u00a0sunitinib in advanced renal cell carcinoma: biomarker analysis of\u00a0the phase 3 JAVELIN Renal 101 trial","volume":"26","author":"Motzer","year":"2020","journal-title":"Nat Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923012759?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923012759?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:32:30Z","timestamp":1761856350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702923012759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S2059702923012759"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.102034","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.102034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"102034"}}